Browsing Tag
complement inhibitors
2 posts
How the VALIANT Phase 3 data may strengthen EMPAVELI’s nephrology market position
Find out how Sobi’s VALIANT Phase 3 data may reshape EMPAVELI’s nephrology market position and what it means for rare kidney disease growth.
Can selective Bb inhibition give NovelMed Therapeutics an edge in the multibillion-dollar PNH drug market?
NovelMed Therapeutics advances Ruxoprubart with Phase II PNH results and a subcutaneous trial. Discover how it could reshape the complement inhibitor market.